adobe stock - JHVEPhoto PartnershipBoehringer Ingelheim inks deal with Tessallate BioBoehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments. more ➔
adobe stock - peterschreiber.media US tariff policy Roche and Novartis react to US tariffsDespite the World Trade Organisation’s (WTO) ban of tariffs on pharmaceuticals, US President Donald Trump has announced he would consider imposing tariffs on pharmaceutical products. In a fast reaction, … more ➔
Image by freepikDairy alternativesWhey Waste Finds New Life as ProteinFrench dairy heavyweight Bel Group has teamed up with Standing Ovation in a bid to transform surplus whey from cheese production into high-value casein proteins using precision fermentation. The collaboration … more ➔
uniqure NVGene TherapyAMT-130 gets FDA breakthrough therapy designationAmsterdam-based uniQure NV’s gene therapy candidate AMT-130 has been granted FDA Breakthrough Therapy Designation for the treatment of the neurodegenerative Huntington’s disease. more ➔
RijksoverheidGovernanceNetherlands Sets Sights on Global Biotech LeadershipThe Netherlands has set itself an ambitious goal: to be among the global leaders in biotechnology by 2040. This vision is backed by an initial commitment of €1.3 billion in funding. more ➔
123rf.com/guniitaNeurodegenerative DisordersNLS and Kadimastem: Swiss-israeli merger in ALSNLS Pharmaceutics secures US$2m equity funding and signs US$25m equity facility to support merger with Kadimastem (Israel) to combine expertise in aiming to become a leader in regenerative medicine in … more ➔
wikicommonsUnited KingdomUK Government invests millions into new health data serviceUK focuses on digital health research: £600m (US$764m) for new data platform according to the five recommendations of the Sudlow report. more ➔
TIRmed Pharma ABImmunmodulationSwedish TIRmed Pharma raises 4,3m€ against atopic dermatitisTIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety … more ➔
Menarini GroupPartnershipMenarini and ERBC collaborateFrench ERBC and Menarini Biotech from Italy forge a new strategic alliance to accelerate biopharmaceutical development. more ➔
Freepik.comSwitzerlandSwitzerland needs more efforts in biomedicineIn February 2025, the Federal Office of Public Health (FOPH) announced that the Masterplan in Biomedicine will be discontinued. This sends a troubling signal at a time of growing protectionism and potential … more ➔
adobe stock - JHVEPhoto 
adobe stock - peterschreiber.media 
uniqure NV
Rijksoverheid
123rf.com/guniita
wikicommons
TIRmed Pharma AB
Menarini Group
Freepik.com